Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Titel:
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Auteur:
Lonial, Sagar Lee, Hans C Badros, Ashraf Trudel, Suzanne Nooka, Ajay K Chari, Ajai Abdallah, Al-Ola Callander, Natalie Lendvai, Nikoletta Sborov, Douglas Suvannasankha, Attaya Weisel, Katja Karlin, Lionel Libby, Edward Arnulf, Bertrand Facon, Thierry Hulin, Cyrille Kortüm, K Martin Rodríguez-Otero, Paula Usmani, Saad Z Hari, Parameswaran Baz, Rachid Quach, Hang Moreau, Philippe Voorhees, Peter M Gupta, Ira Hoos, Axel Zhi, Eric Baron, January Piontek, Trisha Lewis, Eric Jewell, Roxanne C Dettman, Elisha J Popat, Rakesh Esposti, Simona Degli Opalinska, Joanna Richardson, Paul Cohen, Adam D